HMPL-A830 / Hutchmed, GSK - LARVOL DELTA

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China (GlobeNewswire) - "The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830....Under the terms of the agreement, HUTCHMED Limited is responsible for the global Phase I development program. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities in its territory. Following the closing of the exclusive license agreement, HUTCHMED Limited expects to receive US$110 million upfront payment shortly, and may receive additional development, regulatory and commercial milestone payments of up to a total of US$1.185 billion, as well as tiered royalties on annual net sales."

Licensing / partnership • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Cancer

HMPL-A830 in Solid Tumors (clinicaltrials.gov) - P1/2 | N=147 | Recruiting | Sponsor: Hutchmed | Trial completion date: Nov 2028 ➔ Dec 2029 | Trial primary completion date: Jun 2028 ➔ May 2029 | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors (GlobeNewswire) - "The first patient received the first dose in China on September 24, 2026....This first-in-human, multicenter, open-label Phase I clinical study evaluates the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HMPL-A830. The current study consists of a Phase Ia dose escalation part to determine the maximum tolerated dose and recommended dose for expansion."

First-in-human • Trial status • Solid Tumor

HMPL-A830, a novel EGFR-directed antibody-targeted therapy conjugate (ATTC) with a potent pan-KRAS inhibitor payload (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Oncology • KRAS

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy (HUTCHMED Press release) - "Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate ('ATTC')...Clinical development will initially focus on colorectal, pancreatic and lung cancer indications. The agreement includes a US$110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of US$1.295 billion, and royalties on net sales....Under the terms of the agreement, HUTCHMED Limited will be responsible for the global phase I development program, which is expected to start in the second half of 2026 (clinicaltrials.gov identifier NCT07718581). The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan."

Licensing / partnership • Trial status • Solid Tumor

HMPL-A830 China/US INDs cleared (The Manila Times) - "Plans for global clinical trial initiation in H2 2026. Preclinical data showed superior potency and safety profiles to antibodies or small molecules with the same target, with data to be presented at a scientific conference."

P1/2 data • Trial status • Solid Tumor

HMPL-A830 in Solid Tumors (clinicaltrials.gov) - P1/2 | N=147 | Not yet recruiting | Sponsor: Hutchmed

First-in-human • New P1/2 trial • Oncology • Solid Tumor